XtalPi Holdings’s Stock Price Plummets by 12.10%, Trading at 7.30 HKD: A Detailed Performance Analysis

XtalPi Holdings (2228)

7.30 HKD -1.00 (-12.10%) Volume: 50.94M

Explore XtalPi Holdings’s stock price at 7.30 HKD, experiencing a significant drop of -12.10% this trading session with a trading volume of 50.94M. With a year-to-date decrease of -22.83%, XtalPi Holdings (2228) continues to attract investor attention.

Latest developments on XtalPi Holdings

XtalPi‘s stock price saw a 5.9% increase today following the debut of Kodexia™, the world’s first closed-loop siRNA platform that combines generative AI with first-principles modeling. This AI-driven platform for siRNA medicines has six programmes in progress, showcasing XtalPi‘s commitment to innovation in drug discovery. The unveiling of Kodexia marks a significant milestone for XtalPi Holdings (SEHK:2228), propelling the company forward in the field of predictive blending models. With XtalPi‘s cutting-edge technology and strategic partnerships, investors are eager to see what the future holds for this groundbreaking platform.

XtalPi Holdings on Smartkarma

Analysts on Smartkarma, such as those from αSK Primers, are covering XtalPi (2228 HK) and providing valuable insights on the company’s performance. In a recent report titled “Primer: XtalPi (2228 HK) – Sep 2026,” analysts highlighted XtalPi as a pioneer in TechBio and automated scientific research. The company has shown significant growth, with revenue expanding to RMB 870.46M in FY2025, gross margins improving to 55.27%, and net income reaching RMB 134.21M. Trading at a Price-to-Book multiple of 3.1x, XtalPi offers institutional investors a unique opportunity in industrial-scale laboratory automation and AI-driven scientific discovery.

A look at XtalPi Holdings Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

According to the Smartkarma Smart Scores, XtalPi has a strong long-term outlook, with a high score in Growth indicating potential for significant expansion in the future. The company leverages cutting-edge technologies such as artificial intelligence and quantum physics to provide innovative solutions for drug discovery and material science, positioning it for continued growth in the biotechnology industry.

While XtalPi scores lower in Dividend, its high scores in Value, Resilience, and Momentum suggest a solid foundation and ability to adapt to market changes. With a focus on research and development solutions, XtalPi is well-equipped to navigate challenges and capitalize on opportunities in the evolving biotech landscape. Overall, XtalPi‘s innovative approach and strong performance across key factors bode well for its future success in the industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma